Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05862051 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

Study acronym: RESOLUTE
StatusActive, Not Recruiting
PhaseNot applicable
Started2021-12-14
View on ClinicalTrials.gov ↗
This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment including the impact on survival, compared to continued standard first-line systemic treatment for oligometastatic colorectal cancer.

Amendment record

Amended 4 times since 2023-05-15; most recent filed 2026-05-05. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-05-05
Amendment Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v4
2023-10-15
Amendment Study Status v3
2023-06-15
Amendment Study Status, Outcome Measures v2
2023-06-06
Amendment Study Status, Outcome Measures v1
2023-05-15
Original filing
Trial Details
NCT Number NCT05862051
Lead Sponsor Australasian Gastro-Intestinal Trials Group
Collaborators: Walter and Eliza Hall Institute of Medical Research, Cancer Council Victoria
Conditions Colorectal Cancer, Oligometastatic Disease
Enrollment 6 participants
Start Date 2021-12-14
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-08